What the jury will actually decide in the case of Elon Musk vs. Sam Altman

B
Baseinsider Team
Author
Articles
May 18, 2026
2 min read
101 views
What the jury will actually decide in the case of Elon Musk vs. Sam Altman
A California jury is now weighing a pivotal lawsuit between Elon Musk and OpenAI co-founders Sam Altman and Greg Brockman, with Microsoft also named in the case. The jury's decision will focus on whether OpenAI misused Musk's donations, if the organization and Microsoft benefited unfairly, and questions around corporate governance. The verdict could have major implications for OpenAI's structure and future operations.

What the jury will actually decide in the case of Elon Musk vs. Sam Altman

A jury in California is now deliberating over key questions that will determine the future of OpenAI, as Elon Musk brings legal action against OpenAI’s co-founders, Sam Altman and Greg Brockman, and major partner Microsoft. While courtroom discussions have explored OpenAI’s leadership changes and business decisions, the jurors must answer several focused legal issues:

Key Issues the Jury Must Decide

  • Breach of Charitable Trust: Did OpenAI and its leaders violate Elon Musk’s intention for his donations to support a nonprofit, or were his contributions misapplied?
  • Unjust Enrichment: Did the defendants personally benefit from Musk’s donations via OpenAI’s for-profit activities?
  • Aiding and Abetting: Was Microsoft aware of restrictions on Musk’s donations and did it play a role in harming his interests?

OpenAI’s Legal Defense

  • Statute of Limitations: OpenAI argues that Musk’s complaints relate to actions that occurred before the legal deadlines and are no longer valid.
  • Unreasonable Delay: They contend Musk waited too long to bring his claims, making them unfair.
  • Unclean Hands: OpenAI alleges Musk himself behaved unfairly, including launching rival projects and trying to control OpenAI’s for-profit arm.

Main Arguments from Both Sides

Musk’s Claims

Musk’s legal team says he donated with clear intent to establish an independent nonprofit aiming to distribute AI’s benefits broadly. They argue that Microsoft’s $10 billion investment in 2023 signaled an abandonment of this mission in favor of profit, enriching founders and investors at the foundation’s expense.

OpenAI’s Response

OpenAI’s witnesses have testified that specific restrictions on Musk’s donations were never established, and all funds were used for nonprofit aims well before Musk’s lawsuit. They maintain that for-profit initiatives still support the foundation’s mission, and the board continues to oversee both arms of the organization.

Microsoft’s Position

Microsoft asserts it was unaware of any conditions attached to Musk’s donations and denies influencing decisions that would go against OpenAI’s nonprofit objectives.

What’s Next?

If Musk prevails, OpenAI may be forced to overhaul its operations or dissolve its for-profit component. However, the next phase of court hearings will clarify any remedies or consequences, unless the jury first rules against Musk.

For a detailed breakdown, read the original article by Tim Fernholz on TechCrunch.

Related Articles

Really, you made this without AI? Prove it

Really, you made this without AI? Prove it

As AI-generated content becomes more common, creative professionals are exploring 'AI-free' labels to clearly mark genuine human-made works. However, there's debate over which labels are trustworthy and how to reliably verify authenticity, with blockchain and manual audits among the solutions. The industry faces challenges in defining 'human-made' and agreeing on a universal standard.

Apr 04, 2026 2 min read
AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Isomorphic Labs, a spinoff from DeepMind, is preparing to launch human trials for drugs designed with advanced AI. Using tech like AlphaFold and a new tool called IsoDDE, the company aims to revolutionize drug discovery and treatment, with an ambitious mission to tackle major diseases.

Apr 28, 2026 2 min read